查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1539203

肌萎缩侧索硬化症 (ALS) 市场：全球规模、份额、趋势分析、机会、预测，2019-2030 年

Amyotrophic Lateral Sclerosis Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019-2030, Segmented By Type; By Treatment; By End User; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球肌萎缩侧索硬化症 (ALS) 市场预计将以复合年增长率大幅扩张，到 2030 年将超过 14.5 亿美元。

全球肌萎缩侧索硬化症 (ALS) 市场的推动因素包括 ALS 患病率的上升、认识的提高、治疗方法方案的进步以及更有效治疗方法，得益于政府的资助，该市场正在蓬勃发展。

领先的策略咨询和市场研究公司 BlueWeave Consulting 在最近的一项研究中估计，2023 年全球肌萎缩侧索硬化症 (ALS) 市场以金额为准将达到 9.02 亿美元。 BlueWeave 预测，在 2024 年至 2030 年的预测期内，全球肌萎缩侧索硬化症 (ALS) 市场规模将以 7.10% 的复合年增长率增长，到 2030 年将达到 14.56 亿美元。全球肌萎缩侧索硬化症 (ALS) 市场的驱动因素包括盛行率的增加、医学研究的进步以及对 ALS 认识的提高。诊断技术的改进和治疗 ALS 的生物技术投资的增加是主要原因。此外，政府对罕见疾病研究的支持和倡议，以及製药公司和研究机构之间的合作，也支持了市场的成长。治疗 ALS 的新治疗方法的开发和临床试验数量的增加进一步推动了全球肌萎缩侧索硬化症 (ALS) 市场的成长。

机会 - 新治疗方法研究和发展计划

肌萎缩侧索硬化症（ALS）全球市场的成长主要是由旨在发现新治疗方法的不断增加的研发倡议所推动的。製药公司和研究机构大力投资研发，开发基因疗法、干细胞疗法和候选药物等创新疗法。这些治疗方法进展预计将改善患者预后，提供更有效的治疗选择，推动市场成长，并为改善 ALS 管理带来希望。

地缘政治紧张局势加剧对肌萎缩侧索硬化症（ALS）全球市场的影响

地缘政治紧张局势的加剧可能会对全球肌萎缩侧索硬化症（ALS）市场产生重大影响。国际贸易和供应链的中断可能会导致 ALS 治疗药物的生产和分配延迟。加强监管和贸易限制可能会影响基本药物和医疗设备的供应。此外，ALS 研究的资金可能会被转用于解决眼前的地缘政治问题，从而减缓治疗方法进展。外汇波动和经济不稳定可能会增加医疗保健提供者和患者的成本。总体而言，地缘政治不稳定可能会阻碍获得有效的 ALS 治疗和市场开发，从而影响患者护理和市场成长。

ALS药物的主要最终使用者是专科医院。

全球肌萎缩侧索硬化症（ALS）市场的最终用户是专业设施以及研究和学术机构。专业医疗机构为全球肌萎缩侧索硬化症 (ALS) 市场最终用户的成长做出了重大贡献。这是因为 ALS 患者可以获得专门的治疗和先进的治疗方案。这些设施提供诊断、多学科治疗和临床试验等综合服务，使其成为患者的首选，并赋予他们在市场上的竞争优势。

竞争格局

全球肌萎缩侧索硬化症 (ALS) 市场竞争激烈，众多公司都在争夺更大的市场占有率。市场的主要企业包括三菱田边製药、大冢製药、BrainStorm Therapeutics、Biogen Inc.、Corestem、AB Science、F. Hoffmann-La Roche AG、Biohaven Pharmaceutical、Sun Pharmaceutical 和 Ionis Pharmaceuticals, Inc.。这些公司正在增加对研发活动、併购、合资、联盟、授权合约的投资，并推出新产品和服务，以进一步巩固其在全球肌萎缩侧索硬化症（ALS）市场的地位。

该报告的详细分析提供了有关全球肌萎缩侧索硬化症（ALS）市场的成长潜力、未来趋势和统计数据的资讯。它还重点关注推动市场总规模预测的因素。该报告致力于提供全球肌萎缩侧索硬化症 (ALS) 市场的最新技术趋势以及产业见解，以帮助决策者做出明智的策略决策。此外，我们也分析了市场的成长动力、挑战和竞争力。

目录

第一章 研究框架

第 2 章执行摘要

第三章全球肌萎缩侧索硬化症 (ALS) 市场洞察

  • 产业价值链分析
  • DROC分析
    • 生长促进因子
      • 世界各地 ALS 发病率不断增加
      • ALS 治疗的医学研究和技术进展
      • 医疗保健支出和不断提高的医疗意识
      • 易患神经系统疾病的老年人口增加
    • 抑制因素
      • ALS 治疗方案高成本
      • 目前的治疗方法效果有限
      • 药品核准严格监理要求
    • 机会
      • 新治疗方法的研究和开发工作
      • 製药公司与研究机构的合作
      • 用于早期检测的诊断工具的技术进步
    • 任务
      • 对实验性 ALS 治疗的伦理担忧
      • 不同地区获得 ALS 治疗的机会不平等
  • 科技进步/最新趋势
  • 法律规范
  • 波特五力分析

第四章全球肌萎缩侧索硬化症（ALS）市场：行销策略

第五章全球肌萎缩侧索硬化症（ALS）市场：价格分析

第六章全球肌萎缩侧索硬化症 (ALS) 市场：区域分析

第七章全球肌萎缩侧索硬化症（ALS）市场概述

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按类型
      • 散发性肌萎缩侧索硬化症 (SALS)
      • 遗传性肌萎缩侧索硬化症 (FALS)
    • 透过治疗
      • 药品
      • 物理治疗
      • 呼吸治疗
      • 语言治疗
      • 其他的
    • 按最终用户
      • 专业中心
      • 研究/学术机构
      • 其他的
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲（中东/非洲）

第八章 北美肌萎缩侧索硬化症（ALS）市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 透过治疗
    • 按最终用户
    • 按国家/地区
      • 美国
      • 加拿大

第九章欧洲肌萎缩侧索硬化症（ALS）市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 透过治疗
    • 按最终用户
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第十章亚太地区肌萎缩侧索硬化症（ALS）市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 透过治疗
    • 按最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲和纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 亚太地区其他国家

第十一章拉丁美洲肌萎缩侧索硬化症（ALS）市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 透过治疗
    • 按最终用户
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲

第十二章中东和非洲肌萎缩侧索硬化症（ALS）市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 透过治疗
    • 按最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 中东和非洲其他地区

第十三章竞争格局

  • 主要企业及其产品列表
  • 2023年全球肌萎缩侧索硬化症（ALS）市场占有率分析
  • 透过管理参数进行竞争基准化分析
  • 重大策略发展（合併、收购、联盟等）

第14章地缘政治紧张局势加剧对全球肌萎缩侧索硬化症（ALS）市场的影响

第十五章 公司简介（公司简介、财务矩阵、竞争格局、关键人员、主要竞争对手、联络方式、策略展望、SWOT分析）

  • Mitsubishi Tanabe Pharma Corporation
  • Otsuka Pharmaceutical Co., Ltd
  • BrainStorm Therapeutics
  • Biogen Inc.
  • Corestem
  • AB Science
  • F.Hoffmann-La Roche AG
  • Biohaven Pharmaceutical
  • Sun Pharmaceutical
  • Ionis Pharmaceuticals, Inc.
  • 其他主要企业

第十六章 主要策略建议

第十七章调查方法

简介目录
Product Code: BWC24582

Global Amayotrophic Lateral Sclerosis (ALS) Market Size to Expand at Significant CAGR to Surpass USD 1.45 Billion by 2030

Global Amayotrophic Lateral Sclerosis (ALS) Market is thriving due to rising ALS prevalence, increased awareness, advancements in therapeutic options, and government funding in enhancing research and development efforts for more effective treatments.

BlueWeave Consulting, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Amayotrophic Lateral Sclerosis (ALS) Market size by value at USD 902 million in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Amayotrophic Lateral Sclerosis (ALS) Market size to expand at a CAGR of 7.10% reaching a value of USD 1,456 million in 2030. Global Amyotrophic Lateral Sclerosis (ALS) Market is driven by increasing incidence rates, advancements in medical research, and rising awareness about ALS. Enhanced diagnostic techniques and growing investment in biotechnology for ALS treatment contribute significantly. Additionally, governments' support and initiatives for rare disease research, along with collaborations between pharmaceutical companies and research institutions, propel market growth. The development of novel therapies and increasing clinical trials for ALS treatments further boost the growth of Global Amayotrophic Lateral Sclerosis (ALS) Market.

Opportunity - R&D initiatives for novel therapies

The growth of Global Amyotrophic Lateral Sclerosis (ALS) Market is significantly driven by increased research and development initiatives aimed at discovering novel therapies. Pharmaceutical companies and research institutions are investing heavily in R&D to develop innovative treatments, such as gene therapies, stem cell therapies, and novel drug candidates. These advancements are expected to improve patient outcomes and provide more effective treatment options, fueling market growth and offering hope for better management of ALS.

Impact of Escalating Geopolitical Tensions on Global Amayotrophic Lateral Sclerosis (ALS) Market

Escalating geopolitical tensions can significantly impact the Global Amyotrophic Lateral Sclerosis (ALS) Market. Disruptions in international trade and supply chains may lead to delays in the production and distribution of ALS medications and therapies. Increased regulatory scrutiny and trade restrictions can affect the availability of essential drugs and medical devices. Additionally, funding for ALS research may be diverted to address immediate geopolitical concerns, slowing advancements in treatment options. Fluctuations in currency exchange rates and economic instability can increase costs for healthcare providers and patients. Overall, geopolitical instability can hinder the accessibility and development of effective ALS treatments, impacting patient care and market growth.

Specialty Centers Are Major End Users of ALS Therapies

Global Amyotrophic Lateral Sclerosis (ALS) Market is comprised of specialty centers and research & academic institutes as end users. The specialty centers segment is a higher contributor to the growth of Global Amyotrophic Lateral Sclerosis (ALS) Market by end user. The segment dominates due to the specialized care and advanced treatment options provided by these centers, which cater specifically to ALS patients. These facilities offer comprehensive services, including diagnostics, multidisciplinary care, and access to clinical trials, making them the preferred choice for patients and driving their prominence in the market.

Competitive Landscape

Global Amayotrophic Lateral Sclerosis (ALS) Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd, BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Amayotrophic Lateral Sclerosis (ALS) Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Amayotrophic Lateral Sclerosis (ALS) Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technology trends in Global Amayotrophic Lateral Sclerosis (ALS) Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Amyotrophic Lateral Sclerosis (ALS) Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing prevalence of ALS globally
      • 3.2.1.2. Advances in medical research and technology for ALS treatment
      • 3.2.1.3. Growing healthcare expenditure and awareness
      • 3.2.1.4. Rising geriatric population susceptible to neurological disorders
    • 3.2.2. Restraints
      • 3.2.2.1. High cost of ALS treatment options
      • 3.2.2.2. Limited effectiveness of current therapies
      • 3.2.2.3. Stringent regulatory requirements for drug approval
    • 3.2.3. Opportunities
      • 3.2.3.1. Research and development initiatives for novel therapies
      • 3.2.3.2. Collaborations between pharmaceutical companies and research institutions
      • 3.2.3.3. Technological advancements in diagnostic tools for early detection
    • 3.2.4. Challenges
      • 3.2.4.1. Ethical concerns related to experimental ALS therapies
      • 3.2.4.2. Uneven access to ALS treatments across different regions
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Amyotrophic Lateral Sclerosis (ALS) Market: Marketing Strategies

5. Global Amyotrophic Lateral Sclerosis (ALS) Market: Pricing Analysis

6. Global Amyotrophic Lateral Sclerosis (ALS) Market: Geographical Analysis

7. Global Amyotrophic Lateral Sclerosis (ALS) Market Overview

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share and Forecast
    • 7.2.1. By Type
      • 7.2.1.1. Sporadic ALS (SALS)
      • 7.2.1.2. Familial ALS (FALS)
    • 7.2.2. By Treatment
      • 7.2.2.1. Medication
      • 7.2.2.2. Physical Therapy
      • 7.2.2.3. Respiratory Therapy
      • 7.2.2.4. Speech Therapy
      • 7.2.2.5. Others
    • 7.2.3. By End User
      • 7.2.3.1. Specialty Centers
      • 7.2.3.2. Research & Academic Institutes
      • 7.2.3.3. Others
    • 7.2.4. By Region
      • 7.2.4.1. North America
      • 7.2.4.2. Europe
      • 7.2.4.3. Asia Pacific (APAC)
      • 7.2.4.4. Latin America (LATAM)
      • 7.2.4.5. Middle East and Africa (MEA)

8. North America Amyotrophic Lateral Sclerosis (ALS) Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.1.1. By Type
      • 8.2.4.1.2. By Treatment
      • 8.2.4.1.3. By End User
      • 8.2.4.2. Canada
      • 8.2.4.2.1. By Type
      • 8.2.4.2.2. By Treatment
      • 8.2.4.2.3. By End User

9. Europe Amyotrophic Lateral Sclerosis (ALS) Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. Germany
      • 9.2.4.1.1. By Type
      • 9.2.4.1.2. By Treatment
      • 9.2.4.1.3. By End User
      • 9.2.4.2. United Kingdom
      • 9.2.4.2.1. By Type
      • 9.2.4.2.2. By Treatment
      • 9.2.4.2.3. By End User
      • 9.2.4.3. Italy
      • 9.2.4.3.1. By Type
      • 9.2.4.3.2. By Treatment
      • 9.2.4.3.3. By End User
      • 9.2.4.4. France
      • 9.2.4.4.1. By Type
      • 9.2.4.4.2. By Treatment
      • 9.2.4.4.3. By End User
      • 9.2.4.5. Spain
      • 9.2.4.5.1. By Type
      • 9.2.4.5.2. By Treatment
      • 9.2.4.5.3. By End User
      • 9.2.4.6. Belgium
      • 9.2.4.6.1. By Type
      • 9.2.4.6.2. By Treatment
      • 9.2.4.6.3. By End User
      • 9.2.4.7. Russia
      • 9.2.4.7.1. By Type
      • 9.2.4.7.2. By Treatment
      • 9.2.4.7.3. By End User
      • 9.2.4.8. The Netherlands
      • 9.2.4.8.1. By Type
      • 9.2.4.8.2. By Treatment
      • 9.2.4.8.3. By End User
      • 9.2.4.9. Rest of Europe
      • 9.2.4.9.1. By Type
      • 9.2.4.9.2. By Treatment
      • 9.2.4.9.3. By End User

10. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Treatment
    • 10.2.3. By End User
    • 10.2.4. By Country
      • 10.2.4.1. China
      • 10.2.4.1.1. By Type
      • 10.2.4.1.2. By Treatment
      • 10.2.4.1.3. By End User
      • 10.2.4.2. India
      • 10.2.4.2.1. By Type
      • 10.2.4.2.2. By Treatment
      • 10.2.4.2.3. By End User
      • 10.2.4.3. Japan
      • 10.2.4.3.1. By Type
      • 10.2.4.3.2. By Treatment
      • 10.2.4.3.3. By End User
      • 10.2.4.4. South Korea
      • 10.2.4.4.1. By Type
      • 10.2.4.4.2. By Treatment
      • 10.2.4.4.3. By End User
      • 10.2.4.5. Australia & New Zealand
      • 10.2.4.5.1. By Type
      • 10.2.4.5.2. By Treatment
      • 10.2.4.5.3. By End User
      • 10.2.4.6. Indonesia
      • 10.2.4.6.1. By Type
      • 10.2.4.6.2. By Treatment
      • 10.2.4.6.3. By End User
      • 10.2.4.7. Malaysia
      • 10.2.4.7.1. By Type
      • 10.2.4.7.2. By Treatment
      • 10.2.4.7.3. By End User
      • 10.2.4.8. Singapore
      • 10.2.4.8.1. By Type
      • 10.2.4.8.2. By Treatment
      • 10.2.4.8.3. By End User
      • 10.2.4.9. Vietnam
      • 10.2.4.9.1. By Type
      • 10.2.4.9.2. By Treatment
      • 10.2.4.9.3. By End User
      • 10.2.4.10. Rest of APAC
      • 10.2.4.10.1. By Type
      • 10.2.4.10.2. By Treatment
      • 10.2.4.10.3. By End User

11. Latin America Amyotrophic Lateral Sclerosis (ALS) Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Treatment
    • 11.2.3. By End User
    • 11.2.4. By Country
      • 11.2.4.1. Brazil
      • 11.2.4.1.1. By Type
      • 11.2.4.1.2. By Treatment
      • 11.2.4.1.3. By End User
      • 11.2.4.2. Mexico
      • 11.2.4.2.1. By Type
      • 11.2.4.2.2. By Treatment
      • 11.2.4.2.3. By End User
      • 11.2.4.3. Argentina
      • 11.2.4.3.1. By Type
      • 11.2.4.3.2. By Treatment
      • 11.2.4.3.3. By End User
      • 11.2.4.4. Peru
      • 11.2.4.4.1. By Type
      • 11.2.4.4.2. By Treatment
      • 11.2.4.4.3. By End User
      • 11.2.4.5. Rest of LATAM
      • 11.2.4.5.1. By Type
      • 11.2.4.5.2. By Treatment
      • 11.2.4.5.3. By End User

12. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Market

  • 12.1. Market Size & Forecast, 2019-2030
    • 12.1.1. By Value (USD Billion)
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By Treatment
    • 12.2.3. By End User
    • 12.2.4. By Country
      • 12.2.4.1. Saudi Arabia
      • 12.2.4.1.1. By Type
      • 12.2.4.1.2. By Treatment
      • 12.2.4.1.3. By End User
      • 12.2.4.2. UAE
      • 12.2.4.2.1. By Type
      • 12.2.4.2.2. By Treatment
      • 12.2.4.2.3. By End User
      • 12.2.4.3. Qatar
      • 12.2.4.3.1. By Type
      • 12.2.4.3.2. By Treatment
      • 12.2.4.3.3. By End User
      • 12.2.4.4. Kuwait
      • 12.2.4.4.1. By Type
      • 12.2.4.4.2. By Treatment
      • 12.2.4.4.3. By End User
      • 12.2.4.5. South Africa
      • 12.2.4.5.1. By Type
      • 12.2.4.5.2. By Treatment
      • 12.2.4.5.3. By End User
      • 12.2.4.6. Nigeria
      • 12.2.4.6.1. By Type
      • 12.2.4.6.2. By Treatment
      • 12.2.4.6.3. By End User
      • 12.2.4.7. Algeria
      • 12.2.4.7.1. By Type
      • 12.2.4.7.2. By Treatment
      • 12.2.4.7.3. By End User
      • 12.2.4.8. Rest of MEA
      • 12.2.4.8.1. By Type
      • 12.2.4.8.2. By Treatment
      • 12.2.4.8.3. By End User

13. Competitive Landscape

  • 13.1. List of Key Players and Their Offerings
  • 13.2. Global Amyotrophic Lateral Sclerosis (ALS) Market Share Analysis, 2023
  • 13.3. Competitive Benchmarking, By Operating Parameters
  • 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Impact of Escalating Geopolitical Tensions on Global Amyotrophic Lateral Sclerosis (ALS) Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 15.1. Mitsubishi Tanabe Pharma Corporation
  • 15.2. Otsuka Pharmaceutical Co., Ltd
  • 15.3. BrainStorm Therapeutics
  • 15.4. Biogen Inc.
  • 15.5. Corestem
  • 15.6. AB Science
  • 15.7. F.Hoffmann-La Roche AG
  • 15.8. Biohaven Pharmaceutical
  • 15.9. Sun Pharmaceutical
  • 15.10. Ionis Pharmaceuticals, Inc.
  • 15.11. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

  • 17.1. Qualitative Research
    • 17.1.1. Primary & Secondary Research
  • 17.2. Quantitative Research
  • 17.3. Market Breakdown & Data Triangulation
    • 17.3.1. Secondary Research
    • 17.3.2. Primary Research
  • 17.4. Breakdown of Primary Research Respondents, By Region
  • 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable